End-of-day quote
Taipei Exchange
06:00:00 2024-07-09 pm EDT
|
5-day change
|
1st Jan Change
|
35.6
TWD
|
-1.11%
|
|
+0.71%
|
+3.49%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
922.5
|
836.7
|
657.8
|
1,432
|
1,325
|
1,524
|
Enterprise Value (EV)
1 |
978.7
|
1,014
|
1,334
|
1,455
|
1,075
|
1,364
|
P/E ratio
|
-39.3
x
|
-50.4
x
|
-24.3
x
|
36
x
|
997
x
|
-19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
1.45%
|
Capitalization / Revenue
|
17.2
x
|
13.2
x
|
4.77
x
|
13.8
x
|
15.6
x
|
6.59
x
|
EV / Revenue
|
18.2
x
|
16
x
|
9.67
x
|
14
x
|
12.6
x
|
5.9
x
|
EV / EBITDA
|
-59.8
x
|
-132
x
|
225
x
|
-431
x
|
-109
x
|
83.4
x
|
EV / FCF
|
-12.8
x
|
-18.4
x
|
26.5
x
|
-11,378
x
|
559
x
|
160
x
|
FCF Yield
|
-7.78%
|
-5.45%
|
3.77%
|
-0.01%
|
0.18%
|
0.63%
|
Price to Book
|
3.55
x
|
3.28
x
|
2.33
x
|
3.03
x
|
1.72
x
|
2.23
x
|
Nbr of stocks (in thousands)
|
26,700
|
27,300
|
29,500
|
37,500
|
44,300
|
44,300
|
Reference price
2 |
34.55
|
30.65
|
22.30
|
38.20
|
29.90
|
34.40
|
Announcement Date
|
3/26/19
|
3/31/20
|
4/1/21
|
3/30/22
|
3/30/23
|
3/15/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
53.72
|
63.47
|
137.9
|
103.8
|
85.17
|
231.1
|
EBITDA
1 |
-16.35
|
-7.705
|
5.927
|
-3.378
|
-9.858
|
16.35
|
EBIT
1 |
-26.68
|
-15.81
|
-8.355
|
-16.13
|
-23.81
|
-7.743
|
Operating Margin
|
-49.67%
|
-24.91%
|
-6.06%
|
-15.54%
|
-27.96%
|
-3.35%
|
Earnings before Tax (EBT)
1 |
-23.28
|
-15.57
|
-16.93
|
34.38
|
5.444
|
-110
|
Net income
1 |
-23.45
|
-16.44
|
-26.88
|
32.46
|
1.276
|
-80.04
|
Net margin
|
-43.66%
|
-25.89%
|
-19.5%
|
31.27%
|
1.5%
|
-34.63%
|
EPS
2 |
-0.8784
|
-0.6085
|
-0.9195
|
1.060
|
0.0300
|
-1.810
|
Free Cash Flow
1 |
-76.18
|
-55.23
|
50.26
|
-0.1279
|
1.921
|
8.542
|
FCF margin
|
-141.82%
|
-87.02%
|
36.45%
|
-0.12%
|
2.26%
|
3.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
847.94%
|
-
|
-
|
52.24%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
150.57%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
0.5000
|
Announcement Date
|
3/26/19
|
3/31/20
|
4/1/21
|
3/30/22
|
3/30/23
|
3/15/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
56.2
|
177
|
676
|
22.5
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
250
|
160
|
Leverage (Debt/EBITDA)
|
-3.437
x
|
-22.98
x
|
114
x
|
-6.663
x
|
-
|
-
|
Free Cash Flow
1 |
-76.2
|
-55.2
|
50.3
|
-0.13
|
1.92
|
8.54
|
ROE (net income / shareholders' equity)
|
-8.63%
|
-4.33%
|
-4.53%
|
7.33%
|
0.21%
|
-14.2%
|
ROA (Net income/ Total Assets)
|
-3.9%
|
-2.03%
|
-0.59%
|
-1.14%
|
-2%
|
-0.51%
|
Assets
1 |
600.9
|
810.4
|
4,592
|
-2,854
|
-63.86
|
15,763
|
Book Value Per Share
2 |
9.730
|
9.340
|
9.570
|
12.60
|
17.40
|
15.40
|
Cash Flow per Share
2 |
2.640
|
1.320
|
3.010
|
1.200
|
8.300
|
5.570
|
Capex
1 |
22.5
|
58.2
|
-
|
-
|
-
|
4.2
|
Capex / Sales
|
41.89%
|
91.7%
|
-
|
-
|
-
|
1.82%
|
Announcement Date
|
3/26/19
|
3/31/20
|
4/1/21
|
3/30/22
|
3/30/23
|
3/15/24
|
|
1st Jan change
|
Capi.
|
---|
| +3.49% | 48.94M | | +26.53% | 76.12B | | -5.11% | 23.38B | | +12.55% | 8.69B | | -4.45% | 7.91B | | -35.53% | 6.45B | | +23.69% | 5.75B | | +3.37% | 4.16B | | -7.46% | 3.89B | | +12.84% | 3.25B |
Pharmaceuticals Wholesale
|